Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bioheart, a biotechnology company, has announced that it is planning to spin-off or sell off its interest in several non-core technology platforms in order to intensify its strategic focus on the treatment of patients suffering from heart failure.
Subscribe to our email newsletter
The technologies planned for spin-off or sell off include: Biopace, a biological pacemaker; MyoValve, a cell seeding method for repairing and building biological heart valves; EndoCell, a system for bedside preparation of adipose tissue for delivery of endothelial progenitor cells to the adventitia of coronary arteries for prevention of restenosis following balloon angioplasty, stenting or atherectomy; and AortaCell, a cell compositions and delivery systems for repairing aortic aneurysms or for reinforcing the neck area in aortas repaired with an endovascular stent graft.
Bioheart holds the rights to multiple patents and patents pending related to these non-core technologies as well as proprietary know-how and trade secrets.
In addition, Bioheart is seeking a strategic partner for the development of its bi-ventricular pacemaker technology, called MyoStim, which utilizes a patented electrical stimulation software program and an additional pacemaker lead to enhance cell transplantation.